The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
Authors
Keywords
-
Journal
Viruses-Basel
Volume 12, Issue 9, Pages 934
Publisher
MDPI AG
Online
2020-08-25
DOI
10.3390/v12090934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Will we need novel combinations to cure HBV infection?
- (2020) Geoffrey Dusheiko LIVER INTERNATIONAL
- Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection
- (2020) Zhongji Meng et al. Frontiers in Immunology
- Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL
- (2020) Tzu-Ning Tseng et al. Clinical Gastroenterology and Hepatology
- A year-long extended release nanoformulated cabotegravir prodrug
- (2020) Tanmay A. Kulkarni et al. NATURE MATERIALS
- Long-acting antiretroviral therapy
- (2020) Vicente Soriano et al. NATURE MATERIALS
- Genomic modeling of hepatitis B virus integration frequency in the human genome
- (2019) Ondrej Podlaha et al. PLoS One
- Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)
- (2019) Kin Seng Liem et al. GUT
- Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment
- (2019) Te-Ling Ma et al. PLoS One
- Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B
- (2018) George V. Papatheodoridis et al. HEPATOLOGY
- Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B
- (2018) Wen-Juei Jeng et al. HEPATOLOGY
- Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy
- (2018) Tung-Hung Su et al. JOURNAL OF INFECTIOUS DISEASES
- The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients
- (2018) C.-H. Chen et al. JOURNAL OF VIRAL HEPATITIS
- Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status
- (2018) Feng Liu et al. Journal of Digestive Diseases
- Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk
- (2018) Yao-Chun Hsu et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir
- (2018) Ming-Te Kuo et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation among Asian Chronic Hepatitis B Patients: A Systematic Review
- (2018) Jiaye Liu et al. HEPATOLOGY
- High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B
- (2017) Gi-Ae Kim et al. GUT
- The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
- (2017) George V. Papatheodoridis et al. HEPATOLOGY
- Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy
- (2017) Yao-Chun Hsu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- (2017) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study
- (2017) Thomas Berg et al. JOURNAL OF HEPATOLOGY
- Immunopathogenesis of Hepatitis B Virus
- (2017) Tai-Chung Tseng et al. JOURNAL OF INFECTIOUS DISEASES
- Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study
- (2017) Jiawei Cao et al. JOURNAL OF INFECTIOUS DISEASES
- Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy
- (2017) C.-H. Hung et al. JOURNAL OF VIRAL HEPATITIS
- HBV DNA Integration: Molecular Mechanisms and Clinical Implications
- (2017) Thomas Tu et al. Viruses-Basel
- Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients
- (2017) C.-H. Chen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
- (2017) Chih-Chien Yao et al. Scientific Reports
- Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg
- (2016) Chia-Chi Wang et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
- (2016) Yao-Chun Hsu et al. Clinical Gastroenterology and Hepatology
- Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study
- (2016) Seong Hee Kang et al. JOURNAL OF MEDICAL VIROLOGY
- Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma
- (2016) Ling-Hao Zhao et al. Nature Communications
- Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B
- (2015) H. Chi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
- (2015) W. Ray Kim et al. CANCER
- Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection
- (2015) Chien-Hung Chen et al. Clinical Gastroenterology and Hepatology
- Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients
- (2015) H.-Y. Pan et al. CLINICAL MICROBIOLOGY AND INFECTION
- Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis
- (2015) Anna S.F. Lok et al. HEPATOLOGY
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
- (2015) S. K. Sarin et al. Hepatology International
- Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients
- (2015) Kyu Sik Jung et al. JOURNAL OF GASTROENTEROLOGY
- Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
- (2015) George V. Papatheodoridis et al. JOURNAL OF HEPATOLOGY
- Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
- (2015) I-Cheng Lee et al. MEDICINE
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients
- (2015) Guo-Hong Ge WORLD JOURNAL OF GASTROENTEROLOGY
- Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B
- (2015) Jie Peng et al. Saudi Journal of Gastroenterology
- Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides
- (2014) V. R. Patwardhan et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs
- (2014) Hyung Rae Sohn et al. BMC INFECTIOUS DISEASES
- Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients
- (2014) J. V. Fernandez-Montero et al. CLINICAL INFECTIOUS DISEASES
- Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study
- (2014) Wai-Kay Seto et al. GUT
- The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment
- (2014) Chien-Hung Chen et al. JOURNAL OF HEPATOLOGY
- Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative
- (2013) Dengming He et al. BMC INFECTIOUS DISEASES
- Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients
- (2013) Wen-Juei Jeng et al. HEPATOLOGY
- Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
- (2013) Barbara Rehermann NATURE MEDICINE
- Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
- (2012) Stephanos J. Hadziyannis et al. GASTROENTEROLOGY
- Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B
- (2012) Patrick T.F. Kennedy et al. GASTROENTEROLOGY
- Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy
- (2012) Ching-Lung Lai et al. HEPATOLOGY
- Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
- (2012) Tetsuya Hosaka et al. HEPATOLOGY
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
- (2012) Patrick Marcellin et al. LANCET
- A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir
- (2011) Minghao Ha et al. ARCHIVES OF VIROLOGY
- Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B
- (2011) Akihiro Matsumoto et al. HEPATOLOGY RESEARCH
- Natural history of chronic hepatitis B REVEALed
- (2011) Chien-Jen Chen et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
- (2010) Ting-Tsung Chang et al. HEPATOLOGY
- No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
- (2010) Andrea Snow-Lampart et al. HEPATOLOGY
- Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
- (2010) Ting-Tsung Chang et al. HEPATOLOGY
- Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy
- (2010) Hyo-Suk Lee et al. JOURNAL OF GASTROENTEROLOGY
- Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients
- (2010) Feng Liu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
- (2008) Patrick Marcellin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis B Virus Infection
- (2008) Jules L. Dienstag NEW ENGLAND JOURNAL OF MEDICINE
- Natural history of hepatitis-related hepatocellular carcinoma
- (2008) David-Yiu-Kuen But WORLD JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More